A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats : Role of oxidative stress, gut microbiota, and PPARγ activation
Copyright © 2022 Elsevier B.V. All rights reserved..
AIMS: Diabetic cardiomyopathy is diagnosed by the development of abnormality in the structure and performance of myocardium in diabetic mellitus (DM) patients. Recent studies reported the association between altered gut microbiota and metabolic disorders like diabetes and cardiovascular diseases. Here, we aimed to investigate the gut-heart axis in an experimental animal model where we developed a novel therapeutic combination of dapagliflozin, crocin prebiotic and Lactobacilli probiotic to correct induced diabetic cardiomyopathy.
MATERIALS AND METHODS: Diabetes mellitus was induced by Intraperitoneal (i.p) streptozotocin in male rats. The experimental design includes the administration of the tested drugs (Crocin, Dapagliflozin) solely and with Lactobacillus, or in combination therapy with and without Lactobacillus to the diabetic rats for six weeks. Clinical and microscopic evaluation scoring for cardiac tissues were determined. Biochemical markers including blood glucose level, adiponectin, resistin, cardiac injury markers, lipid profile, antioxidant enzymes, pro and anti-inflammatory markers were assessed. In addition, quantitative relative expression of PPARγ and TXINP genes and capsase-3 levels were measured. The change in the microbiota abundance was investigated using real-time PCR.
KEY FINDINGS: This study demonstrated the synergistic effect of the triple combination; dapagliflozin, crocin prebiotic, and Lactobacillus fermentum and Lactobacillus delbrueckii probiotic in treating diabetic cardiomyopathy in rats. The triple combination significantly reduced the oxidative, inflammatory, apoptotic activities induced by streptozotocin STZ and helped in restoring the symbiotic gut microbiota.
SIGNIFICANCE: It is worthy to perform this study in clinical trials as a primary step to include crocin and Lactobacilli in the therapeutic protocols of diabetic cardiomyopathy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:931 |
|---|---|
| Enthalten in: |
European journal of pharmacology - 931(2022) vom: 15. Sept., Seite 175172 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khalaf, Eman M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1ULL0QJ8UC |
|---|
| Anmerkungen: |
Date Completed 07.09.2022 Date Revised 08.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejphar.2022.175172 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344640043 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344640043 | ||
| 003 | DE-627 | ||
| 005 | 20231226023236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2022.175172 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344640043 | ||
| 035 | |a (NLM)35944619 | ||
| 035 | |a (PII)S0014-2999(22)00433-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khalaf, Eman M |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats |b Role of oxidative stress, gut microbiota, and PPARγ activation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2022 | ||
| 500 | |a Date Revised 08.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a AIMS: Diabetic cardiomyopathy is diagnosed by the development of abnormality in the structure and performance of myocardium in diabetic mellitus (DM) patients. Recent studies reported the association between altered gut microbiota and metabolic disorders like diabetes and cardiovascular diseases. Here, we aimed to investigate the gut-heart axis in an experimental animal model where we developed a novel therapeutic combination of dapagliflozin, crocin prebiotic and Lactobacilli probiotic to correct induced diabetic cardiomyopathy | ||
| 520 | |a MATERIALS AND METHODS: Diabetes mellitus was induced by Intraperitoneal (i.p) streptozotocin in male rats. The experimental design includes the administration of the tested drugs (Crocin, Dapagliflozin) solely and with Lactobacillus, or in combination therapy with and without Lactobacillus to the diabetic rats for six weeks. Clinical and microscopic evaluation scoring for cardiac tissues were determined. Biochemical markers including blood glucose level, adiponectin, resistin, cardiac injury markers, lipid profile, antioxidant enzymes, pro and anti-inflammatory markers were assessed. In addition, quantitative relative expression of PPARγ and TXINP genes and capsase-3 levels were measured. The change in the microbiota abundance was investigated using real-time PCR | ||
| 520 | |a KEY FINDINGS: This study demonstrated the synergistic effect of the triple combination; dapagliflozin, crocin prebiotic, and Lactobacillus fermentum and Lactobacillus delbrueckii probiotic in treating diabetic cardiomyopathy in rats. The triple combination significantly reduced the oxidative, inflammatory, apoptotic activities induced by streptozotocin STZ and helped in restoring the symbiotic gut microbiota | ||
| 520 | |a SIGNIFICANCE: It is worthy to perform this study in clinical trials as a primary step to include crocin and Lactobacilli in the therapeutic protocols of diabetic cardiomyopathy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiomyopathy | |
| 650 | 4 | |a Crocin | |
| 650 | 4 | |a Dapagliflozin | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Gut microbiota | |
| 650 | 4 | |a Lactobacillus | |
| 650 | 7 | |a Benzhydryl Compounds |2 NLM | |
| 650 | 7 | |a Glucosides |2 NLM | |
| 650 | 7 | |a PPAR gamma |2 NLM | |
| 650 | 7 | |a dapagliflozin |2 NLM | |
| 650 | 7 | |a 1ULL0QJ8UC |2 NLM | |
| 650 | 7 | |a Carotenoids |2 NLM | |
| 650 | 7 | |a 36-88-4 |2 NLM | |
| 650 | 7 | |a Streptozocin |2 NLM | |
| 650 | 7 | |a 5W494URQ81 |2 NLM | |
| 650 | 7 | |a crocin |2 NLM | |
| 650 | 7 | |a 877GWI46C2 |2 NLM | |
| 700 | 1 | |a Hassan, Hanan M |e verfasserin |4 aut | |
| 700 | 1 | |a El-Baz, Ahmed M |e verfasserin |4 aut | |
| 700 | 1 | |a Shata, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Khodir, Ahmed E |e verfasserin |4 aut | |
| 700 | 1 | |a Yousef, Mahmoud E |e verfasserin |4 aut | |
| 700 | 1 | |a Elgharabawy, Rehab Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Nouh, Nehal A |e verfasserin |4 aut | |
| 700 | 1 | |a Saleh, Safaa |e verfasserin |4 aut | |
| 700 | 1 | |a Bin-Meferij, Mashael M |e verfasserin |4 aut | |
| 700 | 1 | |a El-Kott, Attalla F |e verfasserin |4 aut | |
| 700 | 1 | |a El-Sokkary, Mohamed M A |e verfasserin |4 aut | |
| 700 | 1 | |a Eissa, Hanan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 931(2022) vom: 15. Sept., Seite 175172 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
| 773 | 1 | 8 | |g volume:931 |g year:2022 |g day:15 |g month:09 |g pages:175172 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2022.175172 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 931 |j 2022 |b 15 |c 09 |h 175172 | ||